StockWatch
·
Laboratory Analytical Instruments
Quarterly ResultAug 11, 2026, 06:08 AM

Alamar Biosciences Completes IPO, Q2 Revenue Up 82% to $29.4M

AI Summary

Alamar Biosciences completed its Initial Public Offering on April 20, 2026, raising $197.8 million in net proceeds from the sale of 12,937,500 shares at $17.00 per share. This event was preceded by a reverse stock split and the conversion of all preferred stock and convertible notes into common stock. For the second quarter ended June 30, 2026, the company reported an 82% increase in total revenue to $29.4 million, though net loss widened to $13.2 million. The IPO significantly improved the company's cash position and stockholders' equity.

Key Highlights

  • IPO completed April 20, 2026, raising $197.8M net proceeds.
  • 12,937,500 common shares issued in IPO at $17.00 per share.
  • Reverse stock split of one-for-2.418 basis on April 10, 2026.
  • Total revenue for Q2 2026 increased 82% to $29.4 million.
  • Product revenue for Q2 2026 grew to $23.3 million.
  • Net loss for Q2 2026 was $(13.2) million.
  • Cash and cash equivalents increased to $133.0 million.
  • Total stockholders' equity turned positive to $312.9 million.